JP2024514339A - がんを治療する化合物、組成物、及び方法 - Google Patents

がんを治療する化合物、組成物、及び方法 Download PDF

Info

Publication number
JP2024514339A
JP2024514339A JP2023564025A JP2023564025A JP2024514339A JP 2024514339 A JP2024514339 A JP 2024514339A JP 2023564025 A JP2023564025 A JP 2023564025A JP 2023564025 A JP2023564025 A JP 2023564025A JP 2024514339 A JP2024514339 A JP 2024514339A
Authority
JP
Japan
Prior art keywords
optionally substituted
mmol
resulting mixture
group
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514339A5 (https=
Inventor
インジー ビー
ケン カーソン
ジェラルディン シリロ ハリマン
グラハム エイ．ビー． ホーン
ラジーヴ ガンディー ゴヴィンダラジ
ラジア オルドリン デニー
デイビッド ジェイ． ディラー
Original Assignee
ホットスポット セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホットスポット セラピューティクス インコーポレイテッド filed Critical ホットスポット セラピューティクス インコーポレイテッド
Publication of JP2024514339A publication Critical patent/JP2024514339A/ja
Publication of JP2024514339A5 publication Critical patent/JP2024514339A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023564025A 2021-04-16 2022-04-15 がんを治療する化合物、組成物、及び方法 Pending JP2024514339A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163175974P 2021-04-16 2021-04-16
US63/175,974 2021-04-16
US202163281493P 2021-11-19 2021-11-19
US63/281,493 2021-11-19
PCT/US2022/025083 WO2022221704A1 (en) 2021-04-16 2022-04-15 Compounds, compositions and methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2024514339A true JP2024514339A (ja) 2024-04-01
JP2024514339A5 JP2024514339A5 (https=) 2025-04-23

Family

ID=81580947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564025A Pending JP2024514339A (ja) 2021-04-16 2022-04-15 がんを治療する化合物、組成物、及び方法

Country Status (14)

Country Link
US (1) US20240228482A1 (https=)
EP (1) EP4323358A1 (https=)
JP (1) JP2024514339A (https=)
KR (1) KR20240037184A (https=)
AU (1) AU2022256514A1 (https=)
BR (1) BR112023021068A2 (https=)
CA (1) CA3215395A1 (https=)
CL (1) CL2023003068A1 (https=)
CO (1) CO2023015484A2 (https=)
IL (1) IL307732A (https=)
MX (1) MX2023012245A (https=)
PE (1) PE20240767A1 (https=)
TW (1) TW202309023A (https=)
WO (1) WO2022221704A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4359381A4 (en) * 2021-06-21 2025-04-30 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
US20250042896A1 (en) * 2021-10-29 2025-02-06 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Polycyclic compound as cbl-b inhibitor
AU2022379959A1 (en) 2021-11-05 2024-05-09 Genentech, Inc. Lactams as cbl-b inhibitors selective over c-cbl
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
EP4554570A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent
AU2023307165A1 (en) * 2022-07-12 2025-02-06 Hotspot Therapeutics, Inc. Methods of preparation of heterocyclic compounds
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
CA3261875A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR
EP4558504A1 (en) * 2022-07-18 2025-05-28 Insilico Medicine IP Limited Cbl-b inhibitors and methods of uses thereof
WO2024077236A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024077244A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024086730A1 (en) * 2022-10-19 2024-04-25 Hotspot Therapeutics, Inc. Heterocyclic cbl-b inhibitors for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024131939A1 (en) * 2022-12-23 2024-06-27 Insilico Medicine Ip Limited Cbl-b inhibitors and methods of uses thereof
EP4653436A1 (en) * 2023-01-19 2025-11-26 Guangzhou Yufan Nantu Biotechnologies Co., Ltd Heterocyclic compounds, preparation method therefor and use thereof
CN120530105A (zh) * 2023-01-20 2025-08-22 海南先声再明医药股份有限公司 取代的三环化合物及其应用
WO2024227436A1 (en) * 2023-05-04 2024-11-07 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025067342A1 (zh) * 2023-09-27 2025-04-03 北京望实智慧科技有限公司 用作Cbl-b抑制剂的化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019131575A1 (ja) * 2017-12-26 2019-07-04 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除剤
JP2019535689A (ja) * 2016-10-27 2019-12-12 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ４，５−縮環１，２，４−トリアゾロン
JP2020169215A (ja) * 2020-07-15 2020-10-15 住友化学株式会社 複素環化合物を用いる有害節足動物防除方法
WO2020210508A1 (en) * 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
WO2020264398A1 (en) * 2019-06-26 2020-12-30 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740837A1 (de) * 1987-11-27 1989-06-08 Schering Ag Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel
MY150032A (en) * 2007-07-19 2013-11-29 Merck Sharp & Dohme Heterocyclic amide compounds as protein kinase inhibitors
AU2008317353B2 (en) * 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
EP4554570A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent
AU2023307165A1 (en) * 2022-07-12 2025-02-06 Hotspot Therapeutics, Inc. Methods of preparation of heterocyclic compounds
CA3261875A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535689A (ja) * 2016-10-27 2019-12-12 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ４，５−縮環１，２，４−トリアゾロン
WO2019131575A1 (ja) * 2017-12-26 2019-07-04 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除剤
WO2020210508A1 (en) * 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
WO2020264398A1 (en) * 2019-06-26 2020-12-30 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
JP2020169215A (ja) * 2020-07-15 2020-10-15 住友化学株式会社 複素環化合物を用いる有害節足動物防除方法

Also Published As

Publication number Publication date
AU2022256514A1 (en) 2023-10-19
MX2023012245A (es) 2024-03-11
KR20240037184A (ko) 2024-03-21
WO2022221704A1 (en) 2022-10-20
CO2023015484A2 (es) 2023-11-30
TW202309023A (zh) 2023-03-01
CL2023003068A1 (es) 2024-05-03
EP4323358A1 (en) 2024-02-21
BR112023021068A2 (pt) 2024-01-23
PE20240767A1 (es) 2024-04-17
US20240228482A1 (en) 2024-07-11
IL307732A (en) 2023-12-01
CA3215395A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
JP2024514339A (ja) がんを治療する化合物、組成物、及び方法
US11780845B2 (en) FGFR inhibitors and methods of use thereof
TWI874443B (zh) KRas G12D抑制劑
CA2905012C (en) Substituted 7-azabicycles and their use as orexin receptor modulators
JP6494622B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
US20240150377A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator
WO2023067515A1 (en) Thiadiazolyl compounds as dna polymerase theta inhibitors
JP2024505261A (ja) Ｃｄｋ２阻害剤およびその使用方法
BR112021011147A2 (pt) Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas
CA3181162A1 (en) Inhibitors of fibroblast growth factor receptor kinases
AU2018252099B2 (en) Fluorine-substituted indazole compounds and uses thereof
TW202330530A (zh) 咪唑并嗒𠯤ｉｌ－１７抑制劑化合物（二）
WO2024026483A2 (en) Cdk2 inhibitors and methods of using the same
AU2021300831A1 (en) RIP1k inhibitors
TW201710250A (zh) 經取代之喹喏啉衍生物
JP7627269B2 (ja) ＲＯＲγｔ阻害剤、その製造方法及び使用
CN117751115A (zh) 化合物、组合物和治疗癌症的方法
EP4426285A1 (en) Histone deacetylase 6 inhibitor compounds and uses thereof
WO2025193691A1 (en) Bicyclic heteroaromatic compounds as trpml modulators
HK40076948A (en) Kras g12d inhibitors
HK40068242A (en) Rip1 inhibitory compounds and methods for making and using the same
HK40068242B (en) Rip1 inhibitory compounds and methods for making and using the same
HK40082783A (en) Rip1 inhibitory compounds and methods for making and using the same
HK40015368B (en) Fluorine-substituted indazole compounds and uses thereof
HK40015368A (en) Fluorine-substituted indazole compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260216